Relationship between Delayed Breast Cancer Diagnosis and Behavioral Economic Factors and Personality Characteristics.

BACKGROUND: Delays in breast cancer diagnosis can allow the disease to progress to an incurable stage. However, factors that cause patients to delay seeking treatment are unclear. In this study, we aimed to identify behavioral economic factors and personality characteristics of patients with breast cancer who had a delayed diagnosis. METHODS: We analyzed questionnaires completed by 41 patients with breast cancer. A delayed diagnosis was defined if the time between the first symptom and the medical visit was more than 6 months. RESULTS: We found 11 patients who had a delayed diagnosis. The significant characteristics associated with patients with breast cancer who had delayed diagnosis were: (i) less experience with breast cancer screening; (ii) progressive disease stage; and (iii) low time and future time preference. We found no significant behavioral economic factors other than time preference, and personality that differed between patients with breast cancer who did and did not have a delayed diagnosis. CONCLUSION: Low time preference rate is a characteristic of patients with breast cancer who had a delayed diagnosis.

The prevalence of sarcopenia and subtypes in cardiovascular diseases, and a new diagnostic approach.

BACKGROUND: The prevalence of sarcopenia and its subtypes, such as sarcopenic obesity, osteosarcopenia, and osteosarcopenic obesity, is little known in patients with cardiovascular diseases (CVD). METHODS: Physical, motor functional, and nutritional assessments were performed for 230 community-dwelling (CD) adults who came to receive a physical check-up, and 160 patients with CVD who were admitted to our hospital. Sarcopenia was diagnosed according to the Asian Working Group for Sarcopenia guidelines. The subtypes of sarcopenia were consecutively diagnosed according to increased body fat percentage and decreased bone density. RESULTS: The CVD patients had malnutrition when compared to the CD adults. Impaired motor function of the CVD patients occurred in females as compared with males. The prevalence of sarcopenia, osteosarcopenia, and osteosarcopenic obesity was higher in the CVD patients than in the CD adults (16.9% vs. 4.4%, p<0.001; 8.8% vs. 2.6%, p=0.009; and 4.4% vs. 0.9%, p=0.036, respectively). The prevalence of sarcopenia in the participants positively correlated with the serum N-terminal prohormone of brain natriuretic peptide concentration. Sarcopenia in the CVD patients was present in a younger population as compared with sarcopenia in the CD adults. The prevalence odds ratio of sarcopenia in the CVD patients was higher in females (6.40, 95% CI: 2.38-17.25, p<0.001) than males (4.03, 95% CI: 1.02-15.90, p=0.047). Based on the data of this study, we determined a calculation formula to get an index alternative to skeletal muscle index, followed by an easy diagnosis of sarcopenia. The formula was composed of sex, weight, and calf circumference. The sensitivity and specificity for the diagnosis with the index were 80.8% and 95.6%, respectively. CONCLUSIONS: CVD may accelerate sarcopenia, osteosarcopenia, and osteosarcopenic obesity. Our calculation formula for the easy diagnosis of sarcopenia may help in an early diagnosis and prevent it before worsening the patient's prognosis.

Japanese version of the Frontal Assessment Battery for dementia.

The Frontal Assessment Battery (FAB) was developed as a short bedside cognitive and behavioral battery to assess frontal lobe functions. The purpose of this study was to evaluate the validity and reliability of a Japanese version of the FAB to measure cognitive dysfunction in patients with dementia. We studied 25 normal subjects and 105 patients with Alzheimer's disease, n=58, vascular dementia, n=24, and frontotemporal dementia, n=23. The neuropsychological test battery included the FAB, the Mini Mental State Examination (MMSE), a memory test, and the Wisconsin Card Sorting Test (Keio version: KWCST). Patients with dementia performed significantly more poorly than controls on all tests. The FAB showed a good correlation with other cognitive measures: MMSE (r=0.725), KWCST number of categories completed (r=0.654), KWCST number of perseveration errors (r=-0.484), and memory test (r=0.643). Patients with more severe Clinical Dementia Rating scores showed lower scores on the FAB. There was good inter-rater reliability (r=0.972), test-retest reliability (r=0.769), and internal consistency (Cronbach's coefficient alpha=0.715). The FAB is a valid and reliable screening test to evaluate cognitive dysfunction among patients with dementia.